NCT04645069: Phase I Dose Escalation Study of ADG126 in Patients With Advanced Malignancies

NCT04645069
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Immunotherapy, Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with central nervous system disease involvement
https://ClinicalTrials.gov/show/NCT04645069

Comments are closed.

Up ↑